NEW YORK, August 29, 2017 /PRNewswire/ --
If you want a Stock Review on BLCM, CARA, CERS, or CHRS then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. This morning, DailyStockTracker.com revisits the Biotech space, which consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry also includes the manufacturing and marketing of drugs as a result of direct research and development. For assessment are the following equities: Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM), Cara Therapeutics Inc. (NASDAQ: CARA), Cerus Corp. (NASDAQ: CERS), and Coherus Biosciences Inc. (NASDAQ: CHRS). Learn more about these stocks by signing up for their free reports on DailyStockTracker.com at:
On Monday, shares in Houston, Texas headquartered Bellicum Pharmaceuticals Inc. recorded a trading volume of 2.28 million shares, which was above their three months average volume of 752,840 shares. The stock ended the session 13.77% higher at $9.42. The Company's shares are trading 12.89% below their 50-day moving average. Moreover, shares of Bellicum Pharma, which focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the US and internationally, have a Relative Strength Index (RSI) of 51.61.
On August 03rd, 2017, Bellicum Pharma announced that Gregory Naeve, Ph.D. has been appointed as Chief Business Officer, effective August 21st, 2017. Dr. Naeve, who will report to CEO Rick Fair, will lead product and portfolio strategy as well as business development for the Company. The free research report on BLCM is available at:
Stamford, Connecticut headquartered Cara Therapeutics Inc.'s stock closed the day 0.63% higher at $12.83 with a total trading volume of 911,995 shares. The Company's shares have advanced 38.11% since the start of this year. The stock is trading 12.55% below its 200-day moving average. Additionally, shares of Cara Therapeutics, which focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the US, have an RSI of 32.52.
On August 01st, 2017, Cara Therapeutics announced the appointment of Mani Mohindru, Ph.D. as CFO and Chief Strategy Officer, effective August 15th, 2017. Josef Schoell, who has held the CFO position at the Company for more than a decade, will be retiring. Dr. Mohindru most recently served as Chief Strategy Officer at Curis, Inc., where she was instrumental in the development and management of overall corporate strategy. The complimentary report on CARA can be downloaded at:
Shares in Concord, California headquartered Cerus Corp. recorded a trading volume of 650,324 shares. The stock ended yesterday's trading session 1.68% lower at $2.34. The Company's shares have advanced 3.54% in the past month and 2.18% in the previous three months. The stock is trading below its 50-day moving average by 1.86%. Furthermore, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 40.26.
On August 02nd, 2017, Cerus announced that it has entered into a $40-million amended growth capital credit facility with Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide. Under the amended facility, Cerus received an immediate $30-million loan at closing on July 31st, 2017, and has the option to draw another $10 million, subject to achieving a specified revenue milestone. Visit us today and download our complete research report on CERS for free at:
Redwood City, California headquartered Coherus Biosciences Inc.'s stock finished Monday's session 0.71% higher at $14.25 with a total trading volume of 597,782 shares. The Company's shares have advanced 6.34% in the last one month. The stock is trading above its 50-day moving average by 4.79%. Additionally, shares of Coherus Biosciences, which focuses on developing and commercializing biosimilar products worldwide, have an RSI of 60.00.
On August 07th, 2017, Coherus Biosciences reported financial results for the quarter ended June 30th, 2017. For the quarter, cash used in operations was $55.6 million; total revenue was $1.4 million; and net loss was ($55.3) million. Cash, cash equivalents, and investments in marketable securities - short-term totaled $118.3 million as of June 30th, 2017.
On August 08th, 2017, research firm JP Morgan reiterated its 'Overweight' rating on the Company's stock with a decrease of the target price from $32 a share to $25 a share. Get free access to your technical report on CHRS at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.